GLP-1 medication use was associated with lower mortality among colon cancer patients, according to a study published Nov. 11 in Cancer Investigation.
Researchers from the University of California San Diego used real-world clinical data from the University of California Health Data Warehouse to assess any association between GLP-1s and five-year mortality in 6,871 colon cancer patients.
Here are five things to know from the study:
- Five-year mortality among colon cancer patients using GLP-1s was 15.5% compared to 37.1% for patients who were not on GLP-1s.
- GLP-1 users still showed “significantly lower” mortality risk after researchers adjusted the data for age, body mass index, disease severity and other health factors, according to a Nov. 11 news release from UC San Diego.
- The survival benefit was most pronounced in colon cancer patients with a BMI over 35.
- “Beyond regulating blood sugar, GLP-1 receptor agonists reduce systemic inflammation, improve insulin sensitivity and promote weight loss — all factors that can dampen tumor-promoting pathways,” the release said.
- Researchers said further study is needed to determine if the survival benefit can be attributed to a direct anti-cancer effect or an indirect effect from improved metabolic health.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
